Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Cut-Price Generics Program Rebounds But Real Impact Still Limited

Executive Summary

India's cut-price generic drugs scheme appears to have gathered some pace, covering over 700 medicines, offering sharp price differentials over brand name therapies and also garnering some private sector interest. But its on-ground impact in improving affordable access to medicines is still limited, some experts claim.

You may also be interested in...



India Government Procurement Preference Norms – Rising Local Flavour

Increasing local content requirements have been stipulated in the public purchase preference norms for medicines in India. Backward-integrated Indian firms stand to gain but progressive localization requirements for drugs not made in India appear to be a tough ask.

India shapes plan to revitalize cut-price generics scheme

India has outlined a set of initiatives to revive its thus far "unsatisfactory" "Jan Aushadhi" cut-price generic medicines scheme, including a distribution effort beyond the exclusive stores for these products and potentially even offering online purchases and home delivery.

Why India's generics program may have few private sector takers

An Indian government tender for more than 280 drugs under its ambitious "Jan Aushadhi" cut-price medicines program is expected to generate limited interest from leading private players, if the early responses of a number of experts is anything to go by.

Topics

Related Companies

UsernamePublicRestriction

Register

WI964856

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel